RxSight (RXST) Expected to Announce Quarterly Earnings on Tuesday

RxSight (NASDAQ:RXST) will likely be announcing its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $40.23 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

RxSight Stock Performance

Shares of RXST stock opened at $29.60 on Monday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -35.66 and a beta of 1.19. RxSight has a one year low of $26.29 and a one year high of $66.54. The company’s 50-day moving average is $33.14 and its 200 day moving average is $43.76.

Insider Buying and Selling at RxSight

In other news, insider Ilya Goldshleger sold 3,105 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $46.08, for a total value of $143,078.40. Following the transaction, the insider now owns 42,246 shares in the company, valued at $1,946,695.68. This represents a 6.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jesse Anderson Corley bought 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average price of $31.18 per share, with a total value of $44,992.74. Following the completion of the transaction, the director now directly owns 1,443 shares of the company’s stock, valued at $44,992.74. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 13,506 shares of company stock valued at $567,456. 9.36% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on RXST. UBS Group started coverage on shares of RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price target for the company. Jefferies Financial Group assumed coverage on RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Monday, January 13th. Stifel Nicolaus dropped their price objective on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday, January 13th. Finally, Wells Fargo & Company decreased their target price on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, RxSight presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.13.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.